# CRISPR Therapeutics

> CRISPR Therapeutics is a VC fund in Cambridge backing Biotechnology. See 1 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 1
- Last investment: Jun 2024
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/crispr-therapeutics
- X (Twitter): https://www.twitter.com/crisprtx
- Website: http://crisprtx.com/
- Facebook: https://www.facebook.com/CRISPRNews/

CRISPR Therapeutics is a VC fund in Cambridge focused on Biotechnology. CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from theirscientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing.CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

## Contacts

5 contacts available for CRISPR Therapeutics. Shizune tracks 8 team members at CRISPR Therapeutics. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/crispr-therapeutics?utm_source=investor_profile

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Julianne Bruno | Chief Operating Officer | 1 | https://shizune.co/investors/profile/julianne-bruno-36ca |
| Andrew Kernytsky | Senior Director, Head of Genomics and Computational Biology | 0 | https://shizune.co/investors/profile/andrew-kernytsky |
| Chris Gemmiti | Executive Director of Technical Operations | 0 | https://shizune.co/investors/profile/chris-gemmiti |
| Craig Mello | Scientific Founders | 0 | https://shizune.co/investors/profile/craig-mello |
| Daniel Anderson | Scientific Founders | 0 | https://shizune.co/investors/profile/daniel-anderson-2 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Averna Therapeutics | Exsilio's method is based on naturally occurring genetic elements that can accurately insert new genes into cells via RNA intermediate templates. Exsilio employs predictive in-silico modeling and wet lab-based experiments to create such elements for accurate insertion of therapeutic genes into safe harbor regions of disease-relevant cells. | $85M | Series A | Jun 25, 2024 |  |

1 of 1 investments shown.

## Co-investors
- [Arc Ventures](https://shizune.co/investors/profile/arc-ventures-b6d5) — VC Fund, 1 deal together
- [Deep-Insight](https://shizune.co/investors/profile/deep-insight-4989) — VC Fund, 1 deal together
- [Deep Insight](https://shizune.co/investors/profile/deep-insight-6269) — VC Fund, 1 deal together
- [Delos Capital](https://shizune.co/investors/profile/delos-capital-%E5%BA%B7%E7%A6%A7%E5%85%A8%E7%90%83%E6%8A%95%E8%B3%87%E5%9F%BA%E9%87%91) — VC Fund, 1 deal together
- [Innovation Endeavors](https://shizune.co/investors/profile/innovation-endeavors) — VC Fund, 1 deal together
- [Insight Partners](https://shizune.co/investors/profile/insight-partners) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does CRISPR Therapeutics invest in?

CRISPR Therapeutics invests primarily in Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact CRISPR Therapeutics?

Public channels for CRISPR Therapeutics include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at CRISPR Therapeutics?

The team at CRISPR Therapeutics includes Julianne Bruno (Chief Operating Officer), Andrew Kernytsky (Senior Director, Head of Genomics and Computational Biology) and Chris Gemmiti (Executive Director of Technical Operations), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co